U.S. Metals and Mining Stock News

Event context and why Marqeta is on investors’ radar Marqeta (MQ) is back in focus after recent trading left the stock at US$4.81, with a 1 day return of about a 1% decline, a slight gain over the past week, and mixed performance over the past 3 months and year. See our latest analysis for Marqeta. That combination of a 3.66% year to date share price return, a 25.26% total shareholder return over one year, and a 29.16% total shareholder loss over three years suggests momentum has picked up...

If you are wondering whether V.F at around US$20.19 is a bargain or a value trap, you are not alone. The stock has been on many investors' watchlists this year. The share price has moved by 11.7% over the last week and 11.1% over the last month, while the 1-year return of a 4.1% decline and 5-year return of a 72.0% decline paint a very different picture for longer-term holders. This mix of short-term gains and longer-term weakness has kept attention on how the business is repositioning...

If you are wondering whether Magnolia Oil & Gas is attractively priced today, the key question is how its current share price lines up with its underlying business value. The stock closed at US$22.21 most recently, with returns of 1.5% over the last 7 days, a 2.8% decline over 30 days, a 1.2% decline year to date, a 6.1% decline over 1 year, a 0.2% gain over 3 years, and a 172.0% gain over 5 years. Recent coverage of Magnolia Oil & Gas has focused on its share price performance over...

Halozyme Therapeutics (HALO) has been in focus after a new collaboration with Skye Bioscience to apply its ENHANZE drug delivery technology to nimacimab, an investigational obesity treatment, as the company expands into metabolic disease. See our latest analysis for Halozyme Therapeutics. The new Skye Bioscience collaboration and December 2025 ENHANZE agreement with Takeda come as Halozyme’s 1 month share price return of 16.58% and 90 day share price return of 12.53% suggest improving...

Aeva Technologies (AEVA) is back in the spotlight after two CES-linked announcements, including NVIDIA’s adoption of its 4D LiDAR for the DRIVE Hyperion platform and the debut of the Omni sensor for physical AI applications. See our latest analysis for Aeva Technologies. Aeva’s recent CES news arrives after a period of sharp swings, with a 7 day share price return of 27.18% and a 1 year total shareholder return above 200%. However, the 5 year total shareholder return remains deeply negative,...

Kenvue has appointed Madhav Nayak as Vice President and Chief Marketing Officer for the Asia-Pacific region, drawing on his prior leadership roles at Yum! Brands, Meta, and Unilever across marketing, strategy, digital, and commercial functions. By bringing in a CMO with deep experience building global consumer brands in Asia, Kenvue is signaling a stronger push to sharpen its marketing and digital execution in one of its most important growth regions. Next, we’ll explore how Nayak’s...

In early January 2026, Moderna reported positive Phase 3 data and submitted regulatory applications in the U.S., EU, Canada, and Australia for its mRNA-1010 seasonal flu vaccine for adults aged 50 and over. This move highlights Moderna’s effort to broaden its respiratory vaccine lineup beyond COVID-19, aiming to reduce dependence on a single product category and make fuller use of its mRNA platform. We’ll now examine how this progress on mRNA-1010, and its potential to diversify respiratory...

In early January 2026, SPS Commerce, Inc. announced a suite of new products and AI-enabled capabilities, including direct SAP S/4HANA cloud integrations and Shopify system automation, to improve real-time visibility and coordination across complex, omnichannel retail supply chains. The launch of the SPS Commerce Relationship Center and Manufacturing Suite is especially material, as it targets the growing need to onboard new partners efficiently and manage diversified, multi-tier supply...

Hawaiian Electric Industries (HE) has reached preliminary agreements to resolve eight shareholder lawsuits tied to alleged wildfire risk disclosure failures, planning to use US$100 million in insurance proceeds without admitting wrongdoing. See our latest analysis for Hawaiian Electric Industries. The settlement news lands after a sharp shift in sentiment, with the share price at US$13.66 and a 90 day share price return of 25.44% alongside a 1 year total shareholder return of 53.31%. However,...

Carpenter Technology (CRS) is back in focus as investors weigh its role in supplying specialty alloys to aerospace, defense, and industrial customers, with interest tied to themes such as re-arming and reshoring manufacturing. See our latest analysis for Carpenter Technology. After a sharp run that has drawn fresh attention to its aerospace and defense exposure, Carpenter Technology’s shares now trade at US$321.26, with a 90 day share price return of 33.25% and a 1 year total shareholder...

Arcus Biosciences recently outlined its 2026 priorities, including multiple planned data readouts for casdatifan in clear cell renal cell carcinoma and ongoing development of quemliclustat for first-line pancreatic cancer. An interesting angle for investors is how Arcus is positioning casdatifan through both early- and late-line trials as part of a "fast-to-market" approach in kidney cancer while also building an emerging inflammation and immunology franchise. Next, we’ll examine how this...

Why LGI Homes Is On Investors’ Radar Today LGI Homes (LGIH) has been drawing fresh attention as investors reassess the US homebuilder’s share performance, business mix, and recent financial metrics, including revenue, earnings, and longer term total returns. See our latest analysis for LGI Homes. After a sharp 8.4% 1 day share price return to around $46.77 and a 7 day share price return of 8.9%, LGI Homes is showing short term momentum. However, its 1 year total shareholder return of around a...

In recent days, Zillow released its latest Consumer Housing Trends Report and hottest markets forecast, highlighting that nearly three in five renters expect to keep renting in 2026 and that Hartford is projected to see the strongest home price growth with tight inventory conditions. These findings suggest that lifestyle-driven renting and concentrated demand in select markets like Hartford could reshape how households use Zillow’s platforms and services. Next, we'll examine how the rise of...

If you are wondering whether Resideo Technologies is priced attractively or already baking in high expectations, you are in the right place. The stock last closed at US$36.86, with returns of 5.0% over 7 days, 9.8% over 30 days, 4.8% year to date, 63.4% over 1 year, 98.2% over 3 years, and 44.5% over 5 years, which raises fair questions about how much value is now reflected in the share price. Recent coverage has focused on Resideo's position in residential comfort, security and energy...

If you are wondering whether Cadence Bank's current share price offers good value or not, you are in the right place because this article focuses squarely on what investors may be paying for today. Cadence Bank's stock has recently closed at US$45.67, with returns of 6.6% over 7 days, 9.7% over 30 days, 5.7% year to date, 34.3% over 1 year and 76.9% over 5 years. This raises questions about how much of this performance is already reflected in the price. Recent attention on Cadence Bank has...

If you are wondering whether Polaris is fairly priced or has room to run, you are not alone. This article will walk you through what the current valuation signals are really saying. The stock last closed at US$73.60, with returns of 16.4% over the past 7 days, 9.9% over 30 days, 10.7% year to date, 40.2% over 1 year, and longer term returns of a 23.3% decline over 3 years and a 19.6% decline over 5 years, pointing to a mixed picture for investors. Recent attention on Polaris has been shaped...

ANI Pharmaceuticals recently announced that CEO Nikhil Lalwani would present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, with the session available via live and archived webcast on the company’s website for 30 days. This conference appearance comes as ANI’s rare disease portfolio, including Cortrophin Gel and acquired ophthalmology products, underpins strong recent financial performance and growing investor attention. Now we’ll examine how robust 2025 results in...

FactSet Research Systems recently filed its latest Form 10-Q, outlining its recent financial and operational performance across the Americas, EMEA, and Asia Pacific segments. The filing highlights how FactSet is weaving AI-powered tools more deeply into its platform to enhance client insights and streamline workflows worldwide. Next, we’ll explore how FactSet’s expanded AI integration within its platform could influence the company’s existing investment narrative and outlook. We've found 11...

GE HealthCare Technologies (GEHC) has drawn fresh attention after announcing a collaboration with NXP Semiconductors focused on edge AI concepts for anesthesia delivery and neonatal monitoring, with both concepts scheduled to be showcased at CES 2026. See our latest analysis for GE HealthCare Technologies. The edge AI announcement lands after a strong run in the shares, with a 90 day share price return of 24.15% and a 1 year total shareholder return of 2.43%. This suggests that near term...

In early January 2026, OneMain Holdings announced a US$1.00 billion senior notes sale, adding to a balance sheet that already carries a debt-to-equity ratio of 6.6× and serves mainly nonprime borrowers. This move increases an already heavy reliance on leverage, raising fresh questions about how the company balances funding needs against financial flexibility and risk. Next, we’ll examine how issuing US$1.00 billion in new senior notes may reshape OneMain’s investment narrative and...

Leonardo DRS, Inc. recently appointed long-time executive Sally A. Wallace as Executive Vice President and Chief Operating Officer, succeeding new President and CEO John Baylouny as part of a broader leadership transition at the defense electronics company. This elevation of a veteran insider with deep operational and technical credentials signals continuity in execution as Leonardo DRS pursues advanced defense technology programs and international collaborations. We’ll now examine how...

If you are wondering whether Globalstar's recent share price is still good value or already stretched, the next sections will walk through what the current market price might be implying. The stock has had a choppy run, with a 2.1% decline over the last week, a 12.4% decline over the last month, a 6.6% decline year to date, a 101.2% gain over the last year, and a 174.8% return over three years. These moves sit against growing investor interest in satellite connectivity and related telecom...

Biogen (BIIB) is back in focus after Chinese regulators accepted the Biologics License Application for a subcutaneous version of LEQEMBI, highlighting a potential shift toward more convenient Alzheimer’s treatment and influencing recent sentiment around the stock. See our latest analysis for Biogen. The LEQEMBI update lands after a strong 90-day share price return of 26.90% and a 30-day share price return of 5.78%, while the 1-year total shareholder return of 23.38% contrasts with weaker 3...

In early January 2026, Marathon Petroleum drew attention after recent U.S. actions toward Venezuela raised the prospect of greater heavy-crude flows that Gulf Coast refiners, including Marathon’s large Garyville facility, are well equipped to process. Investors are now weighing how Marathon’s ability to handle additional Venezuelan heavy crude could interact with its existing refining advantages and upcoming fourth-quarter 2025 earnings announcement. Next, we’ll examine how Marathon’s...